FDA Asked to Approve Relugolix to Treat Advanced Prostate Cancer

Home / Blog / FDA Asked to Approve Relugolix to Treat Advanced Prostate Cancer
FDA Asked to Approve Relugolix to Treat Advanced Prostate Cancer
April 25, 2020April 25, 2020
0

Myovant Sciences has filed an application with the U.S. Food and Drug Administration (FDA) seeking approval of relugolix  to treat men with advanced prostate cancer. The new drug application (NDA) proposes a single daily dose of 120 mg, given as an oral tablet, based on positive results from the Phase 3 HERO trial (NCT03085095, still recruiting in China). “The submission of our NDA for prostate cancer is a major step towards providing a one pill, once a day potential…

You must be logged in to read/download the full post.